Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Clinical Microbiology and Infectious Diseases

• Publication date

  2015-04-18

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1007/s10096-015-2374-1PMID 25894985
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases.

  2014cited by this paper
• ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.

  2014cited by this paper
• ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi.

  2014cited by this paper
• Molecular identification and characterization of Fusarium spp. associated with sorghum seeds.

  2014cited by this paper
• Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview

  2014cited by this paper
• In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.

  2014cited by this paper
• Towards the Genotyping of Fungi: Methods, Benefits and Challenges

  2014cited by this paper
• Fusarium napiforme systemic infection: case report with molecular characterization and antifungal susceptibility tests

  2014cited by this paper
• Antifungal Susceptibility Profile of Cryptic Species of Aspergillus

  2014influential reference
• ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others.

  2014cited by this paper
• A Five-Year Survey of Dematiaceous Fungi in a Tropical Hospital Reveals Potential Opportunistic Species

  2014cited by this paper
• Complexities associated with the molecular and proteomic identification of Paecilomyces species in the clinical mycology laboratory.

  2014cited by this paper
• Clinical characteristics of biopsy-proven allergic bronchopulmonary mycosis: variety in causative fungi and laboratory findings.

  2014cited by this paper
• Fusarium Infection

  2013cited by this paper
• Fusarium Keratitis: Genotyping, In Vitro Susceptibility and Clinical Outcomes

  2013influential reference
• SNaPAfu: A Novel Single Nucleotide Polymorphism Multiplex Assay for Aspergillus fumigatus Direct Detection, Identification and Genotyping in Clinical Specimens

  2013cited by this paper
• Fusarium Infection: Report of 26 Cases and Review of 97 Cases From the Literature

  2013cited by this paper
• Two cases of feline orbital aspergillosis due to Aspergillus udagawae and A. viridinutans.

  2013cited by this paper
• Targeting Iron Acquisition Blocks Infection with the Fungal Pathogens Aspergillus fumigatus and Fusarium oxysporum

  2013cited by this paper
• Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study)

  2013cited by this paper
• Fusarium keratitis in South India: causative agents, their antifungal susceptibilities and a rapid identification method for the Fusarium solani species complex

  2013cited by this paper
• Invasive aspergillosis caused by cryptic Aspergillus species: a report of two consecutive episodes in a patient with leukaemia.

  2013cited by this paper
• Is Azole Resistance in Aspergillus fumigatus a Problem in Spain?

  2013cited by this paper
• Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study)

  2013influential reference
• Chitin synthase inhibitors as antifungal agents.

  2013cited by this paper
• Clinical Significance and Molecular Characterization of Nonsporulating Molds Isolated from the Respiratory Tracts of Bronchopulmonary Mycosis Patients with Special Reference to Basidiomycetes

  2013cited by this paper
• Aspergillus felis sp. nov., an Emerging Agent of Invasive Aspergillosis in Humans, Cats, and Dogs

  2013cited by this paper
• In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.

  2013cited by this paper
• Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species

  2012influential reference
• Susceptibility of 100 filamentous fungi: comparison of two diffusion methods, Neo-Sensitabs and E-test, for amphotericin B, caspofungin, itraconazole, voriconazole and posaconazole.

  2012cited by this paper
• Resistant Fusarium Keratitis Progressing to Endophthalmitis

  2012cited by this paper
• Successful Medical Management of Recalcitrant Fusarium solani Keratitis: Molecular Identification and Susceptibility Patterns

  2012cited by this paper
• Disseminated Amphotericin-Resistant Fusariosis in Acute Leukemia Patients: Report of Two Cases

  2012cited by this paper
• Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.

  2012cited by this paper
• Fatal outcome after heart transplantation caused by Aspergillus lentulus

  2012cited by this paper
• Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales

  2011influential reference
• In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds

  2011cited by this paper
• Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009

  2011cited by this paper
• Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms

  2011cited by this paper
• Polyphasic Identification and Susceptibility to Seven Antifungals of 102 Aspergillus Isolates Recovered from Immunocompromised Hosts in Greece

  2011cited by this paper
• In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E‐test

  2011cited by this paper
• Accurate and Practical Identification of 20 Fusarium Species by Seven-Locus Sequence Analysis and Reverse Line Blot Hybridization, and an In Vitro Antifungal Susceptibility Study

  2011influential reference
• Susceptibility testing of terbinafine alone and in combination with amphotericin B, itraconazole, or voriconazole against conidia and hyphae of dematiaceous molds.

  2011influential reference
• Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates

  2011influential reference
• Triazole Antifungal Agents in Invasive Fungal Infections

  2011cited by this paper
• Ahlstrand E , Persson L , Tidefelt U , Söderquist B. Alteration of the colonization pattern of coagulase-negative staphylococci in patients undergoing treatment for hematological malignancy. Eur J Clin Microbiol Infect Dis

  2011cited by this paper
• High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease.

  2011cited by this paper
• Apoptosis-inducing antifungal peptides and proteins.

  2011cited by this paper
• Amphotericin B and voriconazole susceptibility profiles for the Fusarium solani species complex: comparison between the E-test and CLSI M38-A2 microdilution methodology

  2011cited by this paper
• European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update

  2011cited by this paper
• Rapid identification of Aspergillus fumigatus within the section Fumigati

  2011cited by this paper
• Current state and perspectives of fungal DNA barcoding and rapid identification procedures

  2010cited by this paper
• Identification of Pseudallescheria and Scedosporium Species by Three Molecular Methods

  2010cited by this paper
• Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy.

  2010cited by this paper
• First case of Trichoderma longibrachiatum infection in a renal transplant recipient in Tunisia and review of the literature.

  2010cited by this paper
• Case report: A rare cause of miliary nodules -- allergic bronchopulmonary aspergillosis.

  2009cited by this paper
• In vitro susceptibility of non-Aspergillus allergenic fungal species to azoles.

  2009influential reference
• Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

  2009cited by this paper
• Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure

  2009cited by this paper
• Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds

  2009cited by this paper
• Molecular Identification of Aspergillus Species Collected for the Transplant-Associated Infection Surveillance Network

  2009influential reference
• Chronic Invasive Aspergillosis caused by Aspergillus viridinutans

  2009cited by this paper
• In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis

  2009cited by this paper
• Invasive aspergillosis due to Neosartorya udagawae.

  2009cited by this paper
• In vitro activity of antifungals against Zygomycetes.

  2009cited by this paper
• Invasive mold infections: recent advances in management approaches

  2009influential reference
• Comparison of Assessment of Oxygen Consumption, Etest, and CLSI M38-A2 Broth Microdilution Methods for Evaluation of the Susceptibility of Aspergillus fumigatus to Posaconazole

  2009cited by this paper
• zole-resistance in Aspergillus: Proposed nomenclature and breakpoints

  2009cited by this paper
• Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.

  2008influential reference
• Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods.

  2008influential reference
• Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption.

  2008cited by this paper
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

  2008cited by this paper
• EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

  2008cited by this paper
• Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

  2008influential reference
• In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.

  2008cited by this paper
• Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

  2008influential reference
• Aspergillus Section Fumigati: Antifungal Susceptibility Patterns and Sequence-Based Identification

  2008influential reference
• Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.

  2007cited by this paper
• In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents

  2007influential reference
• Extensively Drug-resistant Tuberculosis, Italy and Germany

  2007cited by this paper
• Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.

  2007cited by this paper
• Polyphasic taxonomy of Aspergillus section Fumigati and its teleomorph Neosartorya

  2007cited by this paper
• Molecular Studies Reveal Frequent Misidentification of Aspergillus fumigatus by Morphotyping

  2006influential reference
• Mistaken Identity: Neosartorya pseudofischeri and Its Anamorph Masquerading as Aspergillus fumigatus

  2005influential reference
• In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38‐A microdilution method

  2005influential reference
• In vitro susceptibilities of zygomycetes to conventional and new antifungals.

  2003cited by this paper
• In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes

  2002influential reference
• Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000

  2002cited by this paper
• In Vitro Fungicidal Activities of Voriconazole, Itraconazole, and Amphotericin B against Opportunistic Moniliaceous and Dematiaceous Fungi

  2001cited by this paper
• In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole.

  2001influential reference
• PCR Primers That Amplify Fungal rRNA Genes from Environmental Samples

  2000cited by this paper
• In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.

  1998influential reference
• Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi

  1996cited by this paper
• Medically Important Fungi: A Guide to Identification

  1976cited by this paper

• Antifungal Minimal Inhibitory Concentrations of Mold Isolates from Patients with Cancer; Single-Center Experience, 2018–2023

  2025cites this paper
• Invasive Fungal Infections in Immunocompromised Conditions: Emphasis on COVID-19

  2024cites this paper
• In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023.

  2024cites this paper
• Scedosporium boydii finding in an immunocompromised patient and review of the literature.

  2024cites this paper
• In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022)

  2024influential citation
• Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY Antifungal Surveillance Program (2018–2021) and application of single‐site epidemiological cutoff values to evaluate amphotericin B activ

  2023cites this paper
• The COVID-19 Vaccines: A Description of Adverse Events of Reactions Reported in Kansas

  2022cites this paper
• Clinical and Microbiological Characteristics of Aspergillosis at a Chinese Tertiary Teaching Hospital

  2022cites this paper
• Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)

  2022cites this paper
• Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections

  2022cites this paper
• Inhibition of azole-resistant Aspergillus fumigatus biofilm at various formation stages by antifungal drugs, including olorofim.

  2022cites this paper
• Disseminated Infection Due to Neocosmospora (Fusarium) falciformis in a Patient with Acute Myelogenous Leukemia

  2022cites this paper
• In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.

  2021cites this paper
• Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY antifungal surveillance program 2017-2019.

  2021cites this paper
• Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019)

  2021cites this paper
• In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.

  2020cites this paper
• Phaeohyphomycosis

  2020cites this paper
• Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans.

  2020cites this paper
• Identification of Proteases: Carboxypeptidase and Aminopeptidase as Putative Virulence Factors of Fusarium solani Species Complex

  2020cites this paper
• Suscetibilidade Antifúngica in vitro de Agentes de Feohifomicoses Superficiais

  2020cites this paper
• In Vitro Activity of Chlorhexidine Compared with Seven Antifungal Agents against 98 Fusarium Isolates Recovered from Fungal Keratitis Patients

  2019cites this paper
• Scedosporium spp.: Chronicle of an emerging pathogen

  2019cites this paper
• Characteristics and risk factors for mortality of invasive non‐Aspergillus mould infections in patients with haematologic diseases: A single‐centre 7‐year cohort study

  2019cites this paper
• Fungal Keratitis Caused by Colletotrichum dematium: Case Study and Review

  2019cites this paper
• A cluster of scedosporiosis in lung transplant candidates and recipients: The Zurich experience and review of the literature

  2018cites this paper
• Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial

  2018cites this paper
• Removing chaos from confusion: assigning names to common human and animal pathogens in Neocosmospora

  2018cites this paper
• In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi.

  2018cites this paper
• In vitro Antifungal Susceptibility Testing of Clinical and Environmental Fusarium Isolates in Iran

  2018cites this paper
• Reduced Multidrug Susceptibility Profile Is a Common Feature of Opportunistic Fusarium Species: Fusarium Multi-Drug Resistant Pattern

  2017cites this paper
• In vitro antifungal susceptibility of clinical isolates of Fusarium from Colombia.

  2017cites this paper
• Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations.

  2016influential citation
• In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method.

  2016cites this paper
• Scedosporium apiospermum and S. prolificans mixed disseminated infection in a lung transplant recipient: An unusual case of long-term survival with combined systemic and local antifungal therapy in intensive care unit

  2016cites this paper
• Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

  2016cites this paper
• Therapeutic Drug Monitoring of Posaconazole: an Update

  2016cites this paper
• Chronological aging in conidia of pathogenic Aspergillus: Comparison between species.

  2015cites this paper